SCHEMBL1300274

SCHEMBL1300274

CCOC(=O)/C(=C\N(C)C)C(=O)c1ncc(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
CYP11B1 P15538 4/20 0.38
CYP11B2 P19099 4/20 0.38
ABCB1 P08183 1/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPY1R P25929 1/20 0.35
NPY2R P49146 1/20 0.35
POLB P06746 1/20 0.34
DHODH Q02127 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1300275 1.00 NPSR1 (0.44) NPSR1CYP11B1CYP11B2ABCB1KMT2A
SCHEMBL29980176 0.84 NPSR1 (0.45) NPSR1CYP11B1CYP11B2ABCB1KMT2A
SCHEMBL21174039 0.84 NPSR1 (0.45) NPSR1CYP11B1CYP11B2ABCB1KMT2A
SCHEMBL19987092 0.84 NPSR1 (0.45) NPSR1CYP11B1CYP11B2ABCB1KMT2A
SCHEMBL15868733 0.81 CYP11B1 (0.47) NPSR1CYP11B1CYP11B2KMT2AALDH1A1
SCHEMBL14698346 0.81 CYP11B1 (0.47) NPSR1CYP11B1CYP11B2KMT2AALDH1A1
SCHEMBL12646759 0.81 NPSR1 (0.39) NPSR1CYP11B1CYP11B2KMT2ALMNA
SCHEMBL22400089 0.80 HPGD (0.37) NPSR1CYP11B1CYP11B2KMT2ALMNA
SCHEMBL12610995 0.79 NPSR1 (0.40) NPSR1CYP11B1CYP11B2KMT2AALDH1A1
SCHEMBL12610996 0.79 NPSR1 (0.40) NPSR1CYP11B1CYP11B2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
WO-2009089263-A2 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP NPSR1 4732/4885CYP11B1 2508/4885CYP11B2 3189/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP NPSR1 4732/4885CYP11B1 2508/4885CYP11B2 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.